编者按：慢性髓系白血病（CML）是白血病中进展相对缓慢的一种类型。然而一旦疾病进展至急变期，患者的预后将急剧恶化。最近20多年，一系列靶向疗法的涌现正帮助CML患者延长生命。作为全球医药创新的赋能者，药明康德一直以来依托“一体化、端到端”的CRDMO ...

Old friends are the anchors that keep us grounded, even as the tide of life ebbs and flows.” This quote from an unknown author makes an interesting point. By God’s ...

I’m a 63-year-old male diagnosed with chronic myelogenous leukemia, Type 2 diabetes and coronary heart disease. I am 5 feet, 11 inches and weigh 240 pounds. I ...

Terns Pharmaceuticals, Inc. ( TERN) Discusses Efficacy and Safety Data Update for TERN-701 in Chronic Myeloid Leukemia December 8, 2025 4:30 PM EST ...

Molecular responses continue to deepen with extended treatment duration, reaching 60% major molecular response at 21 cycles ...

BOULDER, Colo., Nov. 3, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, ...

The FDA's complete response letter for Dasynoc was due to manufacturing issues, delaying its approval for chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) treatment. Dasynoc, a ...

Cycle Pharmaceuticals (Cycle Pharma) has entered into an exclusive U.S. commercialization agreement with Handa Therapeutics, LLC (Handa), for PHYRAGO, an FDA approved drug for treating two types of ...

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Cycle Pharmaceuticals (Cycle Pharma) has entered into an exclusive U.S. commercialization agreement with Handa Therapeutics, LLC (Handa), for PHYRAGO, an ...

Among the patients with newly diagnosed ALL (n=22), 84% and 100% achieved complete hematologic remission at day 28 and 84, respectively. Asciminib plus dasatinib and prednisone combination treatment ...